What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

View Full Paper

Ask AI

Bookmark

Authors

Cohort analysis reveals comparable progression-free survival in systemic and isolated CNS relapse of DLBCL, indicating treatment challenges.

Patients experiencing systemic relapse had a median progression-free survival of 8 months, while isolated CNS relapse showed 7 months.
In a cohort of 1,351 DLBCL patients, chemotherapy was administered with varying results depending on relapse type.
Analysis included evaluation of ECOG performance status and LDH as factors impacting survival outcomes across relapse patterns.
The study supports the need for novel therapies targeting CNS involvement due to the poor prognosis associated with DLBCL relapses.

Filipová et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cohort analysis reveals comparable progression-free survival in systemic and isolated CNS relapse of DLBCL, indicating treatment challenges.